BeOne Medicines Reports Positive Phase 3 Results for Brukinsa in First-Line Mantle Cell Lymphoma
BeOne Medicines has reported positive Phase 3 results from the MANGROVE trial, showing that Brukinsa combined with rituximab significantly improves progression-free survival in previously untreated mantle cell lymphoma.
Brukinsa | 02/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy